Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Klaus G Parhofer et al, published in European Heart Journal, adding:
”First Lp(a)‑Specific Therapy in Secondary Prevention?
Pelacarsen Slashes Apheresis in Established CVD.
Elevated lipoprotein(a) [Lp(a)] is a frequent, genetically driven and largely lifestyle‑independent risk factor, present in approximately 20% of the general population and up to 25% of patients with ASCVD – yet we still have no approved Lp(a)‑lowering drug.
In the German Phase 3 Lp(a)FRONTIERS APHERESIS trial (51 patients with established CVD, isolated Lp(a) >60 mg/dL and a median of 44 LA sessions/year), pelacarsen 80 mg SC every 4 weeks almost abolished the need for weekly Lp(a) apheresis:
- normalized LA rate from 0.93 to 0.16 (≈99% reduction in odds of requiring LA),
- 69% complete LA avoidance from week 12–52 vs 0% on placebo,
- and ~72–77% sustained Lp(a) lowering, with mainly mild injection‑site reactions.
Huge congratulations to Dr Klaus Parhofer, Elisabeth Steinhagen-Thiessen and all co‑authors on these impressive data.
Pelacarsen may represent a major step toward a targeted, scalable therapy for genetically elevated Lp(a) in secondary prevention.”
Title: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Authors: Klaus G. Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann-Menke, Gunnar H. Heine, Hui Cao, Jessica Schorr, Philippe Ferber, Jing Wang, Enrico Cristante, Björn Müller-Edenborn, Anja Vogt, Volker Schettler, Elisabeth Steinhagen-Thiessen
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders